
Opinion|Videos|April 30, 2025
Perspectives on Coordinated Care: Tagraxofusp for BPDCN Through Shared-Care Models
Author(s)Hetty E. Carraway, MD
An expert discusses how structuring clear roles, fostering communication, and using technology in the shared-care model between academic and community centers, alongside monitoring blood glucose levels, kidney function, and comorbidities, ensures effective collaboration and safe use of tagraxofusp (TAG) therapy.
Advertisement
Episodes in this series

Summary for Physicians:
1. Structuring the Shared-Care Model Between Academic and Community Centers:
- Clear Roles: Define specific roles for academic and community centers to ensure complementary care.
- Communication: Foster regular communication (eg, case discussions, telemedicine) for collaboration and updates.
- Education: Academic centers provide training to keep community physicians informed on best practices.
- Shared Decision-Making: Involve both centers in patient care decisions for comprehensive management.
- Technology: Use electronic health records and telemedicine for seamless information exchange.
2. Monitoring TAG in the Community Setting:
- Blood Glucose: Regularly monitor fasting and postprandial glucose levels to assess therapy effectiveness.
- Kidney Function: Track renal parameters (eg, creatinine, estimated glomerular filtration rate) to detect any adverse effects.
- Adverse Effects: Watch for gastrointestinal issues or hypoglycemia and manage promptly.
- Comorbidities: Monitor for complications in patients with other conditions (eg, cardiovascular disease).
- Adherence: Ensure patients follow the TAG regimen through regular follow-ups and support.
These strategies ensure effective collaboration and safe use of TAG therapy in both academic and community settings.
Advertisement
Related to this article

Five-year OLYMPUS data show Jelmyto (UGN-101) sustains kidney-sparing control in low-grade UTUC, with most responders remaining event-free.

New study shows CT-measured body fat, not BMI, links obesity to higher lung cancer risk via immune T-cell changes—hinting at prevention through weight loss.

The IMpactMF trial was discontinued after an independent committee determined imetelstat was unlikely to improve overall survival.

The EGFR x LGR5 bispecific antibody petosemtamab demonstrated improved overall survival and overall response rate when added to pembrolizumab in head and neck squamous cell carcinoma.

COA urges Supreme Court review of Mississippi 340B contract pharmacy law, spotlighting PBM influence, drug access concerns, and calls for tighter oversight.

LITESPARK-012 data at ESMO 2026 show that adding belzutifan or quavonlimab to pembrolizumab/lenvatinib did not improve survival for advanced kidney cancer.
Advertisement
Advertisement
Trending on Targeted Onc
1
ESMO 2026: ADCs and New Combinations Advance Lung Cancer Care
2
340B Contract Pharmacy Case Rekindles Scrutiny Over Program Intent
3
Novel ADCs Show Responses in Ovarian and Cervical Cancer at ESMO 2026
4
ESMO 2026: New Data Advance Prostate, Kidney, and Bladder Cancer Care
5

